# Shanghai Junshi Biosciences Reports Positive Final Phase 3 NEOTORCH Results for Toripalimab in Resectable NSCLC

> Shanghai Junshi Biosciences reported positive final Phase 3 NEOTORCH results for perioperative toripalimab plus chemotherapy in resectable stage II-III NSCLC.

- Published: 2026-10-28T04:15:16+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-28/junshi-biosciences-neotorch-final-results
- Source: [TradingView](https://www.tradingview.com/news/tradingview:8cba9b4c175cd:0-shanghai-junshi-biosciences-reports-final-phase-3-neotorch-results/)

## Key takeaways

- Final Phase 3 NEOTORCH results showed significant and durable improvements in event-free survival, major pathological response and overall survival for perioperative toripalimab plus chemotherapy in resectable stage II-III non-small cell lung cancer.
- The data included a median follow-up of 48.2 months with no new safety signals.
- China's sNDA for the stage II-III label expansion was accepted in July 2026, following the December 2023 NMPA approval.

Shanghai Junshi Biosciences reported positive final Phase 3 NEOTORCH results for perioperative toripalimab plus chemotherapy in resectable stage II-III non-small cell lung cancer, showing significant and durable improvements in event-free survival, major pathological response and overall survival. [TradingView](https://www.tradingview.com/news/tradingview:8cba9b4c175cd:0-shanghai-junshi-biosciences-reports-final-phase-3-neotorch-results/) published the announcement on October 28, 2026.

## What the NEOTORCH Final Analysis Showed

The final analysis covered patients with resectable stage II-III non-small cell lung cancer treated with perioperative toripalimab plus chemotherapy. The company said the regimen demonstrated significant and durable improvements in event-free survival and overall survival, alongside major pathological response. The data included a median follow-up of 48.2 months, and the company said there were no new safety signals. [Shanghai Junshi Biosciences](https://akta.pro/company-profiles/0009v3u/shanghai-junshi-biosciences) is a Shanghai-headquartered, dual-listed biopharmaceutical company founded in 2012 that develops antibodies for oncology, autoimmune, metabolic and infectious disease patients across China and more than 40 countries.

## Regulatory Path for the Stage II-III Label

China's supplemental new drug application for toripalimab in this setting was accepted in July 2026, according to the announcement. The application seeks to expand the indication from stage IIIA-IIIB to stage II-III. The National Medical Products Administration approved toripalimab for the earlier stage IIIA-IIIB indication in December 2023.

## Toripalimab's Earlier Approvals and Partnerships

According to akta.pro [company records](https://akta.pro/company-data), the NEOTORCH Phase III final analysis in May 2026 met the event-free survival and major pathological response endpoints with a 60% risk reduction in stage II-III resectable non-small cell lung cancer perioperative treatment. The same records show that the NMPA approved toripalimab with RemeGen's disitamab vedotin in May 2026 for first-line HER2-expressing urothelial carcinoma, the 13th Chinese Mainland indication and the first approved domestic immuno-ADC combination. Full-year 2025 total revenue was RMB 2,498 million, a roughly 28% increase year on year, driven primarily by toripalimab domestic sales of RMB 2,068 million, up 38% year on year.

## Junshi's First-Half Results and Earlier Financing

In September 2026, The future of trading reported that Junshi's FY26 first-half revenue was RMB 1.7 billion, up 45%, with a profit of RMB 25.5 million. Research and development expenses fell 14% to RMB 643.94 million, while selling and distribution costs rose 4% to RMB 507.17 million. In June 2025 the company raised RMB 940 million through a placing of new H shares, according to akta.pro company records.

## What Comes Next for the Stage II-III Filing

The supplemental new drug application accepted in July 2026 covers the stage II-III expansion, following the December 2023 approval for stage IIIA-IIIB. The company's own [announcement](http://junshipharma.com) describes the NEOTORCH data.

## Companies in this story

- [Shanghai Junshi Biosciences company profile](https://akta.pro/company-profiles/0009v3u/shanghai-junshi-biosciences) · website: http://junshipharma.com

---
News for Agent · https://newsforagent.com/llms.txt